Article

C. albicans appendicitis in a neutropenic patient after induction chemotherapy


 

A 62-year-old white man with a past medical history of hypertension and essential thrombocytosis diagnosed 17 years ago presented at our institution. He was being treated with hydroxyurea, with which he required occasional blood transfusions and platelets were controlled around 400 x 109/L range. Over a 2-month period, he developed gradually worsening exertional dyspnea, fatigue, decreased appetite, lost about 8 lb in weight. He was found to be pancytopenic, with a total white cell count of 3.26 x 109/L (normal, 3.8-10.6 x 109/L), his hemoglobin level was 7.9 gm/dL (normal, 12.9-16.9 gm/dL), and his platelet count, 46 x 109/L. A bone marrow aspirate and biopsy revealed 100% cellularity, approximately 8%-10% CD34 positive blasts, and numerous atypical and hypolobated dysplastic megakaryocytes with increased reticulin fibrosis. He was diagnosed with myelofibrosis with underlying myeloproliferative disorder, which seemed to be progressing into a more accelerated phase. He was admitted for induction chemotherapy with cytarabine and idarubicin as a bridge to a matched allogeneic stem cell transplant.

*Click on the link to the left for a PDF of the full article.

Recommended Reading

Idelalisib and rituximab produce responses in 97% with CLL
MDedge Hematology and Oncology
Simple conditioning, GVHD prophylaxis yields good hematologic malignancy survival
MDedge Hematology and Oncology
Ensuring optimal adherence to BCR-ABL1 tyrosine kinase inhibitor therapy for chronic myeloid leukemia
MDedge Hematology and Oncology
Obinutuzumab plus chlorambucil packs 1-2 punch against CLL in elderly
MDedge Hematology and Oncology
CD123 differentiates acute GVHD from infections, drug reactions
MDedge Hematology and Oncology
VTE rate triples in pediatric cancer survivors
MDedge Hematology and Oncology
Revised IPSS bests other systems for predicting MDS outcomes
MDedge Hematology and Oncology
New biomarker predicts treatment-resistant GVHD
MDedge Hematology and Oncology
Splenectomy mortality risk similar for malignant and benign disease
MDedge Hematology and Oncology
Omacetaxine for chronic or accelerated phase CML in patients with resistance or intolerance to TKIs
MDedge Hematology and Oncology